Autism Disorder and Treatment Market Research Report - Forecast to 2023

Market Scenario

Autism Spectrum Disorder (ASD) is a range of conditions caused by challenges with social skills, speech and nonverbal communication, repetitive behaviors, along with unique strengths and differences. This condition is caused by different combinations of genetic and environmental influences. Autism tends to show its most-obvious signs between two and three years of age. In various cases, it can be diagnosed within 18 months of the child’s birth.

The global autism disorder and treatment market has been identified as one of the rapidly growing industries, owing to rising prevalence of autism and Pervasive Developmental Disorder (PDD) and rising awareness about autism among the patient population. Autism disorder and treatment is observed as one of the significantly growing markets in the healthcare sector because of initiatives taken by the government of various nations and expected approvals of various off-label treatment therapies by the Food and Drug Association (FDA).

With the upsurge in the market, there are some hindrances faced by the market such as a weak pipeline of drugs for autism disorder and unknown etiology and pathophysiology of ASD.

Global Autism Disorder & Treatment Market is expected to grow at a CAGR of 4.37% during the forecast period 2017–2023.

Intended Audience

- Drugs Manufacturers for Autism disorder
- Drugs Suppliers for Autism disorder
- Training & Service providers for autism disorder
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

Research Methodology
Segmentation

The Global autism disorder & treatment market is segmented by type, treatment type, and drugs.

By type, it is segmented into Asperger Syndrome, Pervasive Developmental Disorder, and others.

By treatment type, it is segmented into ABA (applied behavioral analysis), hyperbaric oxygen therapy, chelation therapy, oxytocin therapy, and others.

By drug, it is segmented into SSRIs, anti-convulsant, stimulants, anti-psychotic. Anti-psychotics are further segmented into Abilify (aripiprazole) and Risperidone.

Figure: Global Autism Disorder & Treatment Market, by Treatment Type, 2016 (%)
ABA is the largest segment, by treatment type in global and expected to grow at a rate of CAGR 4.82% during the forecast period.

The anti-psychotic accounted for the largest market share in global autism disorder & treatment market by drugs and is expected grow with the CAGR of 3.95% for the forecast period.

Regional Analysis

The global autism disorder & treatment market is segmented into four regions namely the Americas, Europe, Asia Pacific, and the Middle East & Africa, with Americas holding the largest market share followed by Europe. In Americas, North America accounted for the largest market owing to the increasing screening of autism cases in this region. Additionally, the approval and expected launch of the atypical anti-psychotic such as Latuda and Namenda is expected to generate increased sales in the U.S. post-approval. Asia Pacific is expected to be the fastest growing market while the Middle East & Africa exhibit steady and growth during the forecast period. As per the epidemiological studies conducted over the past 50 years have suggested that the prevalence of ASD is increasing globally. Some of the factors responsible for the increasing prevalence are improved awareness, expansion of diagnostic criteria, better diagnostic tools and improved reporting.

Key Players

GLOBAL AUTISM DISORDER & TREATMENT MARKET

The global autism disorder & treatment market is expected to reach USD 7,265.1 million by 2023.

TABLE OF CONTENTS

1 REPORT PROLOGUE

2 MARKET INTRODUCTION

2.1 Scope of Study 17
2.2 Research Objective 17
2.3 Assumptions & Limitations 17
2.3.1 Assumptions 17
2.3.2 Limitations 17